Dupixent Study for Alternate Administration

Eligibility: patients =\>18 years old with recurrent chronic rhinosinusitis with nasal polyposis (CRSwNP) despite standard of care (i.e topical medical therapies and full endoscopic sinus surgery) Inclusion criteria: * Age=\>18 y/o with recurrent CRSwNP based on reported symptoms and endoscopic assessment * history of atleast 1 endoscopic sinus surgery * Current use of intranasal corticosteroid spray or irrigation * Active duty servicemembers must be in the area for at least 7 months after starting the medication to complete the necessary follow ups Exclusion Criteria: * Previous use of other biologic therapy in last 6 months * if history of asthma, FEV1\< 50% * history of cystic fibrosis, eosinophilic granulomatosis with polyangiitis, granulomatosis with polyangiitis, kartagener syndrome, primary ciliary dyskinesia * Patient is a pregnant woman, may become pregnant or breastfeeding.